Retatrutide 30mg

Retatrutide is an investigational triple receptor agonist that activates GLP-1, GIP, and glucagon receptors. It is researched for weight management, appetite regulation, glucose metabolism, energy balance, and body composition, and is one of the most closely followed next-generation metabolic research compounds.

Studied for combined effects on satiety signaling, insulin and glucagon pathways, and energy expenditure. GLP-1 and GIP receptor activity are associated with appetite and glucose regulation, while glucagon receptor activity may contribute to energy-use signaling in metabolic research models.

Clinical research in adults with obesity has reported substantial, dose-dependent body-weight reductions over 48 weeks. Ongoing Phase 3 studies continue to evaluate retatrutide in larger obesity, overweight, and cardiometabolic research populations. It is presented as investigational and research-use only, not as an approved therapy.

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity — NEJM/PubMed, 2023
• TRIUMPH obesity Phase 3 study — ClinicalTrials.gov